The European market for orthopedic soft tissue repair exceeded €900 million in 2011.
The orthopedic soft tissue repair market consists of:
The countries covered in this report include:
All market segments were affected by the economic downturn in 2011 due to a slowdown in procedure growth and a decline in pricing. A large dip in the market occurred in 2011, which is largely attributable to drastic price declines, particularly in the HA viscosupplementation segment. The overall market will experience a large boost in 2013 due to the implementation of new regulations by the European Medicines Agency (EMA) that will permit only EMA approved products to be sold. This change will make TiGenix’s premium priced ACI product, ChondroCelect®, the leading product in that market since it was the sole EMA approved product in 2011.
Within the european soft tissue market, companies such as Fidia, Smith & Nephew, Genzyme (Sanofi)lead the market, among many others. This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2018, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.
Buy this report @ http://www.reportsnreports.com/reports/159724-european-markets-for-orthopedic-soft-tissue-sports-medicine-2012.html
